Effects of alendronate with or without hormone replacement therapy on bone mineral density in postmenopausal osteoporotic women

Introduction: Osteoporosis is an important problem in postmenopausal women. The use of best treatment is crucial to attaining appropriate therapeutic and prophylactic outcomes. Combination therapy versus single therapy may develop better results. This study was performed to determine the effects of...

Full description

Bibliographic Details
Main Authors: Fariba Almassinokiani, Mehrak Ashouri Movasagh, Ali Moazamipur
Format: Article
Language:English
Published: Zabansaraye Parsian Novin Mehr Institute 2022-06-01
Series:Journal of Current Oncology and Medical Sciences
Subjects:
Online Access:http://submission.journalofcoms.com/index.php/JCOMS/article/view/43
_version_ 1797861888143392768
author Fariba Almassinokiani
Mehrak Ashouri Movasagh
Ali Moazamipur
author_facet Fariba Almassinokiani
Mehrak Ashouri Movasagh
Ali Moazamipur
author_sort Fariba Almassinokiani
collection DOAJ
description Introduction: Osteoporosis is an important problem in postmenopausal women. The use of best treatment is crucial to attaining appropriate therapeutic and prophylactic outcomes. Combination therapy versus single therapy may develop better results. This study was performed to determine the effects of alendronate alone versus plus hormone replacement therapy (HRT) on bone mineral density (BMD) in Iranian postmenopausal osteoporotic women. Materials and Methods: In this randomized clinical trial 200 consecutive postmenopausal osteoporotic women since 2018 to 2020 were enrolled and randomly assigned to receive either alendronate 70 mg alone or plus HRT 0.625 mg CEE and 2.5 mg medroxyprogesterone acetate. The improvement in BMD, hot flash, vaginal dryness, dyspareunia, and mood disorders was assessed after 12 months and compared across the groups. SPSS software by Kolmogorov-Smirnov, Chi-Square, and Mann-Whitney-U tests. Results: Complete improvement in BMD was seen in 20 and 47 percent in single and combination groups, respectively with statistically significant difference (P=0.001). According to results, the improvements in hot flashes (P=0.048), vaginal dryness (P=0.001), dyspareunia (P=0.002), and mood disorders (P=0.001) in women were better in combination group. Conclusion: The addition of HRT to alendronate can increase the therapeutic effects on BMD and other symptoms in postmenopausal osteoporotic women and its use is recommended.
first_indexed 2024-04-09T22:10:31Z
format Article
id doaj.art-4c1f6452351a47a6a37071a5cd1ce2ea
institution Directory Open Access Journal
issn 2783-3127
language English
last_indexed 2024-04-09T22:10:31Z
publishDate 2022-06-01
publisher Zabansaraye Parsian Novin Mehr Institute
record_format Article
series Journal of Current Oncology and Medical Sciences
spelling doaj.art-4c1f6452351a47a6a37071a5cd1ce2ea2023-03-23T11:20:40ZengZabansaraye Parsian Novin Mehr InstituteJournal of Current Oncology and Medical Sciences2783-31272022-06-0122190195Effects of alendronate with or without hormone replacement therapy on bone mineral density in postmenopausal osteoporotic womenFariba Almassinokiani 0Mehrak Ashouri Movasagh 1Ali Moazamipur 2Gynaecology and Obstetrics Department, Iran University of Medical Sciences, Tehran, IranGynaecology and Obstetrics Department, Iran University of Medical Sciences, Tehran, IranShahid Beheshti University of Medical Sciences, Tehran, IranIntroduction: Osteoporosis is an important problem in postmenopausal women. The use of best treatment is crucial to attaining appropriate therapeutic and prophylactic outcomes. Combination therapy versus single therapy may develop better results. This study was performed to determine the effects of alendronate alone versus plus hormone replacement therapy (HRT) on bone mineral density (BMD) in Iranian postmenopausal osteoporotic women. Materials and Methods: In this randomized clinical trial 200 consecutive postmenopausal osteoporotic women since 2018 to 2020 were enrolled and randomly assigned to receive either alendronate 70 mg alone or plus HRT 0.625 mg CEE and 2.5 mg medroxyprogesterone acetate. The improvement in BMD, hot flash, vaginal dryness, dyspareunia, and mood disorders was assessed after 12 months and compared across the groups. SPSS software by Kolmogorov-Smirnov, Chi-Square, and Mann-Whitney-U tests. Results: Complete improvement in BMD was seen in 20 and 47 percent in single and combination groups, respectively with statistically significant difference (P=0.001). According to results, the improvements in hot flashes (P=0.048), vaginal dryness (P=0.001), dyspareunia (P=0.002), and mood disorders (P=0.001) in women were better in combination group. Conclusion: The addition of HRT to alendronate can increase the therapeutic effects on BMD and other symptoms in postmenopausal osteoporotic women and its use is recommended.http://submission.journalofcoms.com/index.php/JCOMS/article/view/43osteoporosismenopauseprophylaxis
spellingShingle Fariba Almassinokiani
Mehrak Ashouri Movasagh
Ali Moazamipur
Effects of alendronate with or without hormone replacement therapy on bone mineral density in postmenopausal osteoporotic women
Journal of Current Oncology and Medical Sciences
osteoporosis
menopause
prophylaxis
title Effects of alendronate with or without hormone replacement therapy on bone mineral density in postmenopausal osteoporotic women
title_full Effects of alendronate with or without hormone replacement therapy on bone mineral density in postmenopausal osteoporotic women
title_fullStr Effects of alendronate with or without hormone replacement therapy on bone mineral density in postmenopausal osteoporotic women
title_full_unstemmed Effects of alendronate with or without hormone replacement therapy on bone mineral density in postmenopausal osteoporotic women
title_short Effects of alendronate with or without hormone replacement therapy on bone mineral density in postmenopausal osteoporotic women
title_sort effects of alendronate with or without hormone replacement therapy on bone mineral density in postmenopausal osteoporotic women
topic osteoporosis
menopause
prophylaxis
url http://submission.journalofcoms.com/index.php/JCOMS/article/view/43
work_keys_str_mv AT faribaalmassinokiani effectsofalendronatewithorwithouthormonereplacementtherapyonbonemineraldensityinpostmenopausalosteoporoticwomen
AT mehrakashourimovasagh effectsofalendronatewithorwithouthormonereplacementtherapyonbonemineraldensityinpostmenopausalosteoporoticwomen
AT alimoazamipur effectsofalendronatewithorwithouthormonereplacementtherapyonbonemineraldensityinpostmenopausalosteoporoticwomen